By Josh White
Date: Monday 29 Apr 2024
(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.
The FTSE 100 pharmaceuticals giant's first update was on Truqap in combination with 'Faslodex', or fulvestrant, targeting...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news